Skip to main content
OpenTrials
Completed

NCT Number: NCT06658132

A General Anesthesia Regimen for DBS Surgery in Patients With PD

Patients who meet the enrollment criteria and voluntarily join this study will be admitted to the operating room on the day of surgery, and will receive endotracheal intubation under general anesthesia. Induction will be conducted with sufentanil 0.2~0.3ug/kg, rocuronium bromide 0.6mg/kg and propofol 1~2 mg/kg. After successful intubation, mechanical ventilation will be provided with a fresh air flow of 2.0 L/min, a tidal volume of 6~8ml/kg and a respiratory rate of 10~12 times/min to control the end-tidal carbon dioxide between 35~45mmHg. Following that, 20 ml of 0.5% ropivacaine will be applied for bilateral scalp nerve block. The surgeon will then install the stereotactic head frame and take the patients out for CT examination. After returning to the operating room after CT examination, the surgeons will install driving electrodes. During this period, GA will be maintained with sevoflurane, propofol, remifentanil and rocuronium bromide. The depth of anesthesia is monitored using BIS, with a target of 40-65.

During electrode implantation stage: sevoflurane, propofol and rocuronium bromide will be stopped, and esketamine 0.2~0.5mg/kg/h combined with remifentanil 0.5~1ug/kg/min will be used to maintain anesthesia with a target BIS value of 60-70. Patients' blood pressure and heart rate will be controlled to change within less than 30% of the basal value with necessary medication.

If the patient moves during the electrode implantation stage, the rescue plan is to quickly inhale sevoflurane to 0.3 mac, and the number of rescues will be recorded. The vital signs of the patient, MER signal strength, STN discharge frequency, length of STN localization nucleus, and whether the STN boundary is successfully located will be recorded.

During the implantation stage of the pulser, the GA regimen will return to before electrode implantation stage. In other words, sevoflurane + remifentanil + propofol + rocuronium bromide will be used to maintain the depth of anesthesia till the end of the operation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Renji Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200127, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Bilateral STN-DBS surgery is planned for primary PD (meeting the International Movement Disorder Society (MDS) diagnostic criteria for PD);
  • ASA Classes I-III;
  • Age 50-75 years;
  • Informed consent from patients or their families

Exclusion criteria

  • BMI≥28.0kg/m2;
  • comorbid other conditions causing parkinson-like motor symptoms;
  • Previous history of severe head trauma, deformity, or craniocerebral surgery;
  • Previous history of psychiatric and neurological diseases, such as history of overt stroke (ischemic lesion near STN), depression, severe central nervous system depression, basal gangliopathy, schizophrenia, epilepsy, Alzheimer's disease, myasthenia gravis, etc.;
  • Preoperative MoCA scale showed that the patient had dementia;
  • Severe heart, liver, lung, kidney, and immune system diseases;
  • Allergy or contraindication to the trial drug

Treatment and study plan

0.5~1ug/kg/min remifentanil combined with 0.2~0.5mg/kg/h esketamine for the physiological testing phase of DBS surgery.

Drug

Throughout the first and third stages of surgery, all patients receive a traditional induction of anesthesia. Fifteen minutes before the second stage of surgery (MER and clinical assessment), when the burr hole is ready, the propofol and sevoflurane infusion is discontinued, and patients receive 0.5~1ug/kg/min remifentanil combined with 0.2~0.5mg/kg/h esketamine. On completion of the second stage of surgery, the interventional drug is discontinued and propofol combined with sevoflurane is resumed until the end of the third stage.

Primary outcomes

  1. Proportion of MER signal recordings with high NRMS.

    Time frame: During surgery

    Mean NRMS greater than 2.0 after MER recording after STN entry.

Secondary outcomes

  1. MER signal strength

    Time frame: During surgery

  2. Beta band (13-30Hz) oscillations calculated by spectrum analysis during MER recording.

    Time frame: During surgery

  3. Length of STN

    Time frame: During surgery

  4. Proportion of successfully defining STN borders

    Time frame: During surgery

  5. occurrence of cognitive impairment at 7 days postoperatively

    Time frame: at 7 days postoperatively

    MoCA scale score decreased by 2 points compared with preoperatively

  6. occurrence of depression at 7 days postoperatively

    Time frame: at 7 days postoperatively

    HAMD scale score> 20 points

  7. Patient satisfaction at 24 hours after surgery

    Time frame: at 24 hours after surgery

    Analyzed by patient satisfaction assessment scale.

Sponsors and collaborators

Lead sponsor

RenJi Hospital

Other

Registry information

Official study title

An Exploratory Study of a General Anesthesia Regimen for Deep Brain Electrical Stimulation in Patients With Parkinson's Disease

Acronym: GADBS

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 26, 2024
Registry last updated
May 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.